About 15 results found for searched term "p38 MAPK-IN-1" (0.199 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14177 | p38-α MAPK-IN-1 | p38 MAPK |
| p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay. | ||
| M14178 | p38 MAPK-IN-1 | p38 MAPK |
| p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability. | ||
| M1781 | Adezmapimod (SB203580) | p38 MAPK |
| RWJ 64809; PB 203580; Adezmapimod | ||
| Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM. | ||
| M3048 | TAK-715 | p38 MAPK |
| TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. | ||
| M3751 | Losmapimod | p38 MAPK |
| GW-856553X; GSK-AHAB; SB856553 | ||
| Losmapimod (GW856553) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. | ||
| M4469 | Cinnamaldehyde | PPAR |
| Cinnamaldehyde is a naturally occurring flavonoid found in the bark of Cinnamomum cinnamomi and other Cinnamomum species such as camphor and cinnamon, and can act through a variety of signaling pathways, including PPARs, AMPK, PI3K/IRS-1, RBP4-GLUT4, ERK/JNK/p38MAPK, TRPA1-ghrelin, and the Nrf2 pathways.Cinnamaldehyde also has the potential to modulate the activities of PTP1B and α-amylase with antifungal activity and antioxidant activity. | ||
| M5873 | Pexmetinib (ARRY-614) | p38 MAPK |
| ARRY-614 | ||
| Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1. | ||
| M7582 | SB 239063 | p38 MAPK |
| SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. | ||
| M9160 | BMS-582949 | p38 MAPK |
| PS540446; BMS582949 free base | ||
| BMS-582949 is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor with IC50 of 13nM. | ||
| M14174 | BMS-582949 hydrochloride | p38 MAPK |
| BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease. | ||
| M28792 | SD-169 | p38 MAPK |
| SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation. | ||
| M29615 | SR-318 | p38 MAPK |
| SR-318 is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC50 of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity. | ||
| M30587 | Emprumapimod | p38 MAPK |
| PF-07265803 | ||
| Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain. | ||
| M30703 | 12-Oxo phytodienoic acid | NF-κB |
| 12-OPDA | ||
| 12-Oxo phytodienoic acid (12-OPDA, 12-oxo phytodienoic acid) is a plant lipid-derived compound with anti-inflammatory activity that inhibits neuroinflammation by inhibiting Nf-κB and p38 MAPK signaling in cells activated by lipopolysaccharide (LPS).12-Oxo phytodienoic acid can be used in the study of neurodegenerative diseases. | ||
| M30721 | Ralimetinib | p38 MAPK |
| LY2228820 | ||
| Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
